LD-2 disclosure · 4th Quarter - Report
CELGENE CORPORATION
Client
- Location
- New Jersey · United States of America
Registrant
- Description
- 8/1/2004
- Location
- Summit, New Jersey, United States of America
Lobbying activities
2 issuesCopyright/Patent/Trademark
S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.
LobbyistsPATRICK GLIHA
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
LobbyistsPATRICK GLIHA · MATTHEW SCHUMAKER · GREG CHESMORE · STEPHEN RUBRIGHT · ALANNA TEMME
TargetedSENATE · HOUSE OF REPRESENTATIVES